Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical AB to change name to Hansa Biopharma AB

Regulatory information
Lund, Sweden, December 20, 2018-Hansa Medical AB (publ) (Nasdaq Stockholm:HMED) (“Hansa Medical” or the “Company”), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the name change resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018, have been approved by the ‘Bolagsverket’ in Sweden.

The name change will be implemented in the next days and weeks and the Company stock ticker symbol has changed from “HMED” to “HNSA”. 

The information was submitted for publication, through the agency of the contact person set out below, at 2:15 pm CET on December 20, 2018.